•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
This is what HALO produces from top to bottom! Dilution coming once again!
pops or homo
how low will this go charties
Royalties alone are up 20%! from last year .. come on guys
The Earnings report was WAY better then what everyone here was thinking AKA the shorts... This has WINNER all over it. next JNJ. $$
Will be trading back in the single digits soon.
Keep shorting this Pig
Just the usual. Low royalties. Huge expenditure. No news and basically nothing due. This is going down.
Check your monthly chart. I would be surprised if 12.26 is not the bottom.
More of the same today no doubt. Disappointing partner royalties - are Shire selling any HyQ? Huge expenditure mainly on the endless PEG trials. Yet again no news on those trials - whatever happpened to the promised interim readouts on the
I find it interesting that Halo has not commented on or updated their website of the addition of Rituxan Hycela as a product they are part of. I was worried about this, but found it advertised on Genentech. I would have thought they would have at least updated their website. Any thoughts?
Way oversold,they're hiring on a weekly basis.Something big in the woks
earnings tomorrow, should be interesting................present on Thursday, maybe stock poised for a little run, would be nice.
Eat dung HALO! Bwahahahahaha!
Shorts have it right now, should go to $10 after earnings, but still have drugs in the pipeline, will be short term pain, will lose 30% or so and then get back to $12 by end of year.